- Home
- XERS vs XNCR Comparison
XERS vs XNCR Comparison
Compare XERS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | XNCR |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | XERS | XNCR |
|---|---|---|
| Price | $6.05 | $12.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $10.83 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.6M | 785.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | $49,590,000.00 | ★ $125,576,000.00 |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.83 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | 13.65 |
| 52 Week Low | $3.95 | $6.92 |
| 52 Week High | $10.08 | $18.69 |
Technical Indicators
Market Signals| Indicator | XERS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 54.65 |
| Support Level | $4.87 | $12.29 |
| Resistance Level | $7.21 | $12.87 |
| Average True Range (ATR) | 0.26 | 0.80 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 86.02 | 70.51 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.